Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 31, 2013. The report details a specific share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 356,000 Ordinary Shares on July 31, 2013.
- Price Range: Highest price paid was 1,698.00 pence; lowest price paid was 1,678.00 pence.
- Treasury Holdings (Settled): 505,049,512 shares (9.33% of total issued share capital).
- Treasury Holdings (Including Unsettled): 505,405,512 shares (10.30% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,907,086,864 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 356,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.30% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (505,049,512 settled vs. 505,405,512 including unsettled).
- Confirm the denominator for voting rights calculations is 4,907,086,864 shares.
- Check the price paid per share against market rates on July 31, 2013 (range: 1,678.00 to 1,698.00 pence).
- Review the remaining authorization for share buybacks under the May 1, 2013 shareholder mandate.